TOKYO : Researchers in Japan have developed a universal artificial blood substitute designed to carry oxygen and assist in clotting without dependence on blood type compatibility, marking a significant step in trauma medicine and emergency response planning.
The project is being led by teams at the National Defense Medical College and Nara Medical University. The development focuses on addressing structural challenges in conventional blood transfusion systems, including limited shelf life, strict refrigeration requirements, and the need for blood-type matching.
Universal Compatibility and Storage Stability
The artificial blood product, known as Hemoglobin Vesicles (HbV), is engineered to function independently of ABO blood group antigens. By removing blood-type–specific antigens, the substitute is designed to eliminate the need for cross-matching prior to transfusion, reducing preparation time in emergency settings.
Unlike donated red blood cells, which typically have a shelf life of approximately 42 days under refrigerated conditions, the HbV-based product can be stored at room temperature for up to two years. Researchers have also developed a powdered formulation that can be reconstituted by mixing with water, enabling transport and storage in ambulances, remote clinics, and military field units without reliance on cold-chain logistics.
Technical Composition and Mechanism
The artificial oxygen carrier is produced by extracting hemoglobin—the oxygen-binding protein in red blood cells—from expired donor blood or other approved sources. The purified hemoglobin is then encapsulated within liposomes, which are synthetic lipid-based vesicles approximately 250 nanometers in diameter. These vesicles are significantly smaller than natural red blood cells, allowing circulation through narrowed or damaged blood vessels.
The HbV particles are designed to transport oxygen to tissues in cases of severe blood loss or ischemia. Laboratory testing indicates that oxygen delivery performance is comparable to conventional red blood cell transfusion in controlled settings.
To address clotting, researchers incorporated laboratory-engineered platelet substitutes into the formulation. These platelet-mimicking components are coated with fibrinogen gamma-chain peptides to support aggregation at bleeding sites. The integrated design enables the artificial blood to assist in hemostasis while simultaneously restoring oxygen-carrying capacity.
The resulting solution has a distinct purple coloration, reflecting the encapsulated hemoglobin content.
Preclinical Testing Results
Preclinical trials conducted at the National Defense Medical College evaluated the artificial blood substitute in animal models experiencing massive hemorrhage. In controlled experiments involving rabbits with severe blood loss, 10 subjects received the HbV-based treatment.
Six of the treated rabbits survived, a survival rate comparable to those that received standard blood transfusions. In contrast, all rabbits in the control group treated with plasma substitutes without oxygen-carrying capability did not survive. Researchers reported stabilization of vital parameters and restoration of oxygen levels following administration.
These findings supported the transition to early-phase human trials.
Human Clinical Trials
Phase 1 clinical trials began in March 2025 under the supervision of Professor Hiromi Sakai at Nara Medical University. The initial study phase involves healthy adult volunteers and is focused on evaluating safety, tolerability, and pharmacokinetics.
Researchers are monitoring circulation time, metabolic processing, immune response, and potential adverse effects. Pending successful safety evaluation, subsequent phases will assess clinical efficacy in trauma and surgical patients requiring transfusion support.
The research teams aim to complete expanded clinical trials and pursue regulatory approval for broader medical use by 2030.
Applications in Disaster and Military Medicine
The artificial blood substitute is being assessed for use in disaster response scenarios where refrigerated blood supplies may be unavailable due to infrastructure disruption. Earthquakes, tsunamis, and large-scale emergencies can interrupt supply chains, limiting access to compatible donor blood.
The powdered formulation and extended shelf life are expected to support stockpiling for rapid deployment.
Military medical planners are also evaluating potential field applications. Shelf-stable blood products could enable earlier transfusion at the point of injury, particularly during the critical first hour following trauma.
Addressing Demographic and Supply Constraints
Japan’s aging population has contributed to long-term concerns regarding blood supply sustainability. A declining pool of younger donors, combined with increased surgical and transfusion demand among elderly patients, has placed additional pressure on national blood reserves.
Researchers involved in the project have indicated that artificial blood substitutes could supplement conventional blood systems and reduce dependence on donor availability.
Regulatory and Production Considerations
Before widespread clinical use, the product must complete all required phases of clinical testing and meet national regulatory standards for safety and efficacy. Large-scale manufacturing capacity, quality control protocols, and cost considerations remain under evaluation.
If approved, the artificial blood substitute could be integrated into emergency medicine systems, military logistics frameworks, and national disaster preparedness strategies.
Ongoing research will determine long-term safety outcomes, optimal dosing protocols, and compatibility with existing transfusion practices.
——— End of Article ———
